Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Adial Pharmaceuticals, Inc. (ADIL) had Return on Tangible Equity of -54.44% for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
$-2.02M |
|
-- |
|
-- |
|
$2.00M |
|
$-2.00M |
|
$-0.02M |
|
$-2.02M |
|
$-2.02M |
|
$-2.02M |
|
$-2.02M |
|
$-2.02M |
|
$-2.02M |
|
$-2.00M |
|
$-2.00M |
|
1.37M |
|
1.37M |
|
$-1.48 |
|
$-1.48 |
|
| Balance Sheet Financials | |
$4.80M |
|
-- |
|
$0.42M |
|
$5.23M |
|
$1.51M |
|
-- |
|
-- |
|
$1.51M |
|
$3.72M |
|
$3.71M |
|
$3.72M |
|
1.51M |
|
| Cash Flow Statement Financials | |
$-1.61M |
|
-- |
|
$0.32M |
|
$5.88M |
|
$4.58M |
|
$-1.30M |
|
$0.15M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.18 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-1.61M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-54.41% |
|
|
Return on Tangible Equity |
-54.44% |
-38.69% |
|
-54.41% |
|
$2.46 |
|
$-1.18 |
|
$-1.18 |
|